AKEBIA THERAPEUTICS INC (AKBA)

US00972D1054 - Common Stock

1.24  -0.02 (-1.59%)

After market: 1.26 +0.02 (+1.61%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
211.7M
-28.14%		292.5M
38.17%		194.623M
-33.46%		192.87M
-0.90%
EBITDA
YoY % growth
-211.53M
-1.11%		2.99M
101.41%		-6.848M
-329.03%		N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
-249.5M
-2.76%		-34.7M
86.09%		-44.475M
-28.17%		-59.494M
-33.77%		N/AN/A
Operating Margin
-117.86%-11.86%-22.85%-30.85%N/AN/A
EPS
YoY % growth
-1.70
11.92%		-0.44
74.12%		-0.28
36.36%		-0.30
-5.64%		N/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-0.08
44.14%
Revenue
Q2Q % growth		47.271M
18.18%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-13.936M
45.35%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 0.00
100.00%		-0.040.04100.00%
Q3 2023
Q2Q % growth		 -0.08
71.43%		-0.090.017.73%
Q2 2023
Q2Q % growth		 -0.06
-126.09%		-0.03-0.03-135.29%
Q1 2023
Q2Q % growth		 -0.14
60.00%		-0.150.018.50%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 56.196M
1.99%		56.501M-305K-0.54%
Q3 2023
Q2Q % growth		 42M
-13.76%		49.147M-7.147M-14.54%
Q2 2023
Q2Q % growth		 56.4M
-55.38%		60.282M-3.882M-6.44%
Q1 2023
Q2Q % growth		 40M
-35.06%		47.618M-7.618M-16.00%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS14.81% 17.85% -2.35% -1.16%
Revenue14.12% 11.38% -1.85% -1.85%